HT-100: A Powerful Anti-Inflammatory and Anti-Fibrotic
HT-100 is an orally available small molecule drug candidate being developed to reduce fibrosis and inflammation and to promote healthy muscle fiber regeneration in DMD patients. The application of HT-100 to DMD and other fibrotic diseases is based on pioneering work by Dr. Mark Pines at the Volcani Institute in Israel. We have been granted orphan designation for DMD in both the U.S. and EU. Dosing and new patient enrollment in the phase 1b/2a clinical program have been suspended. For more information on the current status of the trial, please visit this link, email us at firstname.lastname@example.org, or visit www.clinicaltrials.gov. To view links to relevant publications please visit this page: Relevant Publications.